Neos Therapeutics Inc (NEOS) Shares Jump Over 60% on FDA Approval of ADHD Drug

Share

Shares of Neos Therapeutics Inc (NASDAQ:NEOS) are up huge this morning after the company announced the FDA approval of Adzenys XR-ODT, a drug used to treat ADHD patients over the age of six. The Amphetamine Extended-Release Orally Disintegrating Tablet is the first of its kind for the treatment of ADHD.

“This first ever FDA approval of a product using our proprietary extended-release, orally disintegrating tablet technology is an important milestone for Neos. We believe that Adzenys XR-ODT will provide an important innovation for treatment in the ADHD market, and we intend to begin educating healthcare providers about our exciting new product immediately. Our full field force launch and product shipments will begin in the second quarter of 2016. We look forward to developing other treatment options for patients utilizing our technology platforms, both in ADHD and beyond,” said Vipin K. Garg, Ph.D., President and CEO of Neos Therapeutics.

The stock is up over 60% in the pre-market this morning. It closed at $9.42 during the last trading session. It is up 6.00% since December 29, 2015 and is uptrending. It has outperformed the S&P500 by 17.02%.

From a total of 3 analysts covering Neos Therapeutics (NASDAQ:NEOS) stock, 3 rate it a “Buy”, 0 a “Sell”, and 0 a “Hold”. This means that 100% of the ratings are positive. The highest target price is $35 while the lowest target price is $26. The mean of all analyst targets is $30.67 which is 225.58% above today’s ($9.42) stock price. Neos Therapeutics was the topic of 5 analyst reports since August 17, 2015 according to the firm StockzIntelligence Inc. RBC Capital Markets maintained shares on November 12 with a “Outperform” rating.

Neos Therapeutics, Inc. is a pharmaceutical company, develops, makes, and commercializes products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies. The company has a market cap of $150.18 million. The Company’s product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. It currently has negative earnings. It makes and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older.

#focuskw=’Neos Therapeutics Inc (NASDAQ:NEOS)’##metadesc=’Shares of Neos Therapeutics Inc (NASDAQ:NEOS) are up huge this morning after the company announced the FDA approval of Adzenys XR-ODT, a drug used to treat ADHD patients over the age of six. The Amphetamine Extended-Release Orally Disintegrating Tablet is the first of its kind for the treatment of ADHD.

“This first ever FDA approval of a product using our proprietary extended-release, orally disintegrating tablet technology is an important milestone for Neos. We believe that Adzenys XR-ODT will provide an important innovation for treatment in the ADHD market, and we intend to begin educating healthcare providers about our exciting new product immediately. Our full field force launch and product shipments will begin in the second quarter of 2016. We look forward to developing other treatment options for patients utilizing our technology platforms, both in ADHD and beyond,” said Vipin K. Garg, Ph.D., President and CEO of Neos Therapeutics.

The stock is up over 60% in the pre-market this morning.’##metarobot=’index’##newskw=’Neos Therapeutics Inc news,Neos Therapeutics Inc – (NASDAQ:NEOS),NASDAQ:NEOS Analyst rating analysis,Stock Analysis,Outlook and potential,NEOS Price change and trend,NEOS stock update’##sitemap=’include’##skipsocial##stockticker=’NASDAQ:NEOS’#

COMMENTS: